ArticleOncotarget2015

Molecular profiling of cetuximab and bevacizumab treatment of colorectal tumours reveals perturbations in metabolic and hypoxic response pathways.

David W Greening et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.